CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-04 | Sabag Mark See "Remarks" | Option exercise | +33,512 | 263,376 | ||
| 2025-03-04 | Sabag Mark See "Remarks" | Option exercise | +18,601 | 281,977 | ||
| 2025-03-04 | Sabag Mark See "Remarks" | Option exercise | +183,169 | 465,146 | ||
| 2025-03-04 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −33,512 | 33,512 | ||
| 2025-03-04 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −18,601 | 55,803 | ||
| 2025-03-04 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −183,169 | 0 | ||
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Option exercise 10b5-1 | +33,512 | 33,512 | ||
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −21,870 | $15.73 | $344K | 11,641 |
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Option exercise 10b5-1 | +20,461 | 20,461 | ||
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −13,353 | $15.73 | $210K | 7,108 |
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Option exercise 10b5-1 | +183,169 | 183,169 | ||
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −56,385 | $15.73 | $887K | 126,784 |
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units 10b5-1 | −33,512 | 33,512 | ||
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units 10b5-1 | −20,461 | 61,384 | ||
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units 10b5-1 | −183,169 | 0 | ||
| 2025-03-04 | Francis Richard D President and CEO | Option exercise 10b5-1 | +50,223 | 295,556 | ||
| 2025-03-04 | Francis Richard D President and CEO | Sale 10b5-1 | −15,514 | $15.73 | $244K | 280,042 |
| 2025-03-04 | Francis Richard D President and CEO | Option exercise · Restricted Share Units 10b5-1 | −50,223 | 150,669 | ||
| 2025-03-04 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −12,936 | $15.56 | $201K | 0 |
| 2025-03-04 | Hughes Eric A See "Remarks" | Sale 10b5-1 | −5,174 | $15.56 | $80K | 0 |
Page 17 of 76 · 1,517 trades